What are our pharmacotherapeutic options for MERS-CoV?
Identifieur interne : 001687 ( PubMed/Checkpoint ); précédent : 001686; suivant : 001688What are our pharmacotherapeutic options for MERS-CoV?
Auteurs : Jaffar A. Al-Tawfiq [Arabie saoudite] ; Ziad A. MemishSource :
- Expert review of clinical pharmacology [ 1751-2441 ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Association de médicaments, Coronavirus du syndrome respiratoire du Moyen-Orient (), Facteurs immunologiques (administration et posologie), Facteurs immunologiques (usage thérapeutique), Humains, Infections à coronavirus (immunologie), Infections à coronavirus (mortalité), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (mortalité), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS ().
- MESH :
- administration et posologie : Antiviraux, Facteurs immunologiques.
- immunologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- mortalité : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- traitement médicamenteux : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Facteurs immunologiques.
- virologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Animaux, Association de médicaments, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (mortality), Coronavirus Infections (virology), Drug Therapy, Combination, Humans, Immunologic Factors (administration & dosage), Immunologic Factors (therapeutic use), Middle East Respiratory Syndrome Coronavirus (drug effects), SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (mortality), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Immunologic Factors.
- chemical , therapeutic use : Antiviral Agents, Immunologic Factors.
- drug effects : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- immunology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- mortality : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Drug Therapy, Combination, Humans.
Abstract
Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease.
DOI: 10.1586/17512433.2014.890515
PubMed: 24580083
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24580083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What are our pharmacotherapeutic options for MERS-CoV?</title><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A" last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation wicri:level="1"><nlm:affiliation>Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Johns Hopkins Aramco Healthcare, Dhahran</wicri:regionArea><wicri:noRegion>Dhahran</wicri:noRegion></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A" last="Memish">Ziad A. Memish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24580083</idno><idno type="pmid">24580083</idno><idno type="doi">10.1586/17512433.2014.890515</idno><idno type="wicri:Area/PubMed/Corpus">001A40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A40</idno><idno type="wicri:Area/PubMed/Curation">001A40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A40</idno><idno type="wicri:Area/PubMed/Checkpoint">001687</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001687</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">What are our pharmacotherapeutic options for MERS-CoV?</title><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A" last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation wicri:level="1"><nlm:affiliation>Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Johns Hopkins Aramco Healthcare, Dhahran</wicri:regionArea><wicri:noRegion>Dhahran</wicri:noRegion></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A" last="Memish">Ziad A. Memish</name></author></analytic><series><title level="j">Expert review of clinical pharmacology</title><idno type="eISSN">1751-2441</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (virology)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Immunologic Factors (administration & dosage)</term><term>Immunologic Factors (therapeutic use)</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (mortality)</term><term>Severe Acute Respiratory Syndrome (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Facteurs immunologiques (administration et posologie)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Humains</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (mortalité)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Therapy, Combination</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24580083</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1751-2441</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of clinical pharmacology</Title><ISOAbbreviation>Expert Rev Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>What are our pharmacotherapeutic options for MERS-CoV?</ArticleTitle><Pagination><MedlinePgn>235-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/17512433.2014.890515</ELocationID><Abstract><AbstractText>Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Tawfiq</LastName><ForeName>Jaffar A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memish</LastName><ForeName>Ziad A</ForeName><Initials>ZA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Clin Pharmacol</MedlineTA><NlmUniqueID>101278296</NlmUniqueID><ISSNLinking>1751-2433</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24580083</ArticleId><ArticleId IdType="doi">10.1586/17512433.2014.890515</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><noCountry><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A" last="Memish">Ziad A. Memish</name></noCountry><country name="Arabie saoudite"><noRegion><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A" last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001687 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001687 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24580083
|texte= What are our pharmacotherapeutic options for MERS-CoV?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24580083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |